Fast track to personalized TCR T cell therapies

Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9.


In this issue of Cancer Cell, Hanada et al. leverage single-cell multi-omics of lung cancer resident lymphocytes to identify phenotypic and transcriptomic signatures differentially expressed by neoantigen-reactive clonotypes. These findings could substantially expedite the selection of neoantigen-specific T cell receptors (TCRs) for individualized T cell therapies.

Trial registration: NCT03412877 NCT04102436 NCT03970382 NCT05194735.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antigens, Neoplasm*
  • Humans
  • Lymphocytes
  • Receptors, Antigen, T-Cell* / genetics
  • T-Lymphocytes
  • Transcriptome


  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell

Associated data